Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MBS314 in relapsed/refractory multiple myeloma
CTR20264046Phase 2Active
- Sponsor
- Mabworks Biotech
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MBS314 in multiple myeloma (MM), sponsored by Mabworks Biotech. Started Oct 2026; status: active.
02
Drugs
MBS314
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20264046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264046.